INTRODUCTION {#s1}
============

Head and neck cancer (HNC) is a heterogeneous disease that can involve multiple sites including oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, paranasal sinuses and salivary glands. Head and neck squamous cell carcinoma (HNSCC) is the most common type, accounting for 90% of all HNC and ranking the sixth leading cancer by incidence worldwide \[[@R1]\]. Heavy use of tobacco and alcohol, human papillomavirus (HPV) infection and xenobiotic exposure are important risk factors for HNSCC \[[@R2], [@R3]\]. This disease is highly curable with a 5-year survival rate approximately from 40% to 60% \[[@R4]\]. The survival rate could be up to 80% for HNSCC patients with a disease at early stage \[[@R5], [@R6]\]. Metastasis and relapse, however, remain a clinical challenge in the management of HNSCCs.

Epithelial-mesenchymal transition (EMT) is a well-established critical mechanism for carcinoma metastasis. During this reprogramming process, epithelial cells acquire sufficient plasticity to become more motile and invasive \[[@R7], [@R8]\]. Several transcription factors (EMT-TFs) have been demonstrated critically involved in EMT regulation and TWIST is known as the principal inducer \[[@R9]\]. TWIST prompts EMT by repressing the expression of epithelial markers, such as E-cadherin, resulting in a loss of epithelial cell-cell adhesion and by upregulating the expressions of mesenchymal genes, such as N-Cadherin \[[@R10]\]. High expression of TWIST has been associated with aggressive tumor properties and poor survival in many cancers, including HNSCC, esophageal, and cervical SCC \[[@R11]--[@R13]\]. In mammals, there are two forms of TWIST, TWIST1 and TWIST2. The two isoforms share more than 90% sequence homology and structural similarity, have similar biochemical properties *in vitro*, and are co-expressed in many cell lines and tissues \[[@R14], [@R15]\]. However, the two isoforms can function differentially in carcinoma metastasis. For example, TWIST2 was reported to inhibit tumor formation in certain types of cancer \[[@R16]--[@R19]\]. Therefore, it is necessary to identify the prognosis roles of each isoform specifically.

Heavy tobacco use is an important risk factor for HNSCC \[[@R2], [@R3]\]. Cigarette smoking has been shown to promote EMT via upregulating EMT-associated gene expressions including *TWIST* \[[@R20]\]. However, whether smoking is associated with poor prognosis of HNSCC is controversial. Some reports argue that smoking \[[@R21]\] has no significant effect on HNSCC survival. In contrast, some studies suggest smoking may result in a significantly increased death risk in HNSCC \[[@R22], [@R23]\].

Gender may be another risk factor for HNSCC. The newly diagnosed cases in men are nearly 3-folds of those in women \[[@R24], [@R25]\]. In addition, the mortality of HNSCC in men is almost 2-folds higher than in women \[[@R24], [@R25]\]. However, a couple of studies did not found statistical difference between males and females in overall survival of HNSCC \[[@R26], [@R27]\]. Therefore, the better insight concerning risk factors for HNSCC is clearly needed.

Given that a high mortality rate is observed in male HNSCC and that tobacco use can regulate EMT, we asked whether gender and smoking could modify the effect of *TWIST1/2* on patient survival in HNSCC. Therefore, the aim of this study is to evaluate the association between *TWIST1*, *TWIST2* and both the clinicopathologic characteristics and survival of HNSCC patients, and the interplay between *TWIST* and either gender or smoking in the survival outcome.

RESULTS {#s2}
=======

Clinicopathologic characteristics of patients {#s2_1}
---------------------------------------------

Table [1](#T1){ref-type="table"} shows the clinical and pathologic characteristics of the 522 patients in the study. The average age of the patients was 60.9 years old (range from 19-90). The majority (73.7%, n=384) of patients were men, and 137 out of 521 were women. Of the patients, 88.1% were Caucasian, followed by African American (9.3%), Asian (2.2%) and American Native (0.4%). Among all the patients, there were 117 non-smokers and 391 smokers. More than half of the patients (n=284) had a stage IV disease, 105 stage III, 98 stage II and 20 stage I. There were 12.2% patients having a tumor with grade I, 58.8% with grade II and 29% with grade III. Tumors were mainly located at the tongue (n=200) and pharynx (n=135). In the patients, 490 were at M0 of metastasis stage and 26 at M1-MX stage. For the 183 patients who had post-radiotherapy information available, 121 (66.1%) received radiotherapy after surgery, while 62 did not. The average overall survival was 21.2 months with the range from 0.07 to 210.8 months for 519 patients with available follow-up information. During the follow-up, 222 of 521 patients with outcome information available died, 229 still lived at the end of the study, and the follow-up for the rest lost (or censored).

###### Characteristics of patients and gene expressions of *TWIST1* and *TWIST2*

  Variable                    N     \%            Range
  --------------------------- ----- ------------- --------------
  Gender                      521                 
  Female                      137   26.3          
  Male                        384   73.7          
  Race                        506                 
  Caucasian                   446   88.1          
  African American            47    9.3           
  Asian                       11    2.2           
  American Native             2     0.4           
  Smoking                     508                 
  No                          117   23.0          
  Yes                         391   77.0          
  Disease Stage               507                 
  I                           20    3.9           
  II                          98    19.3          
  III                         105   20.7          
  IV                          284   56.1          
  Tumor Grade                 517                 
  I                           63    12.2          
  II                          304   58.8          
  III                         150   29.0          
  Tumor site                  521                 
  Tongue                      200   38.4          
  Pharynx                     135   25.9          
  other                       186   35.7          
  Metastasis Stage            516                 
  M0                          490   95.0          
  M1-MX                       26    5.0           
  Radiotherapy                183                 
  No                          62    33.9          
  Yes                         121   66.1          
  Death                       451                 
  No                          229   57.4          
  Yes                         222   42.6          
  Age (Mean ± SD\*, years)    520   60.9 ± 11.9   19 - 90
  Overall survival (months)   519   21.2          0.07 - 210.8
  *TWIST1* (Median)           522   168.2         4.1 - 6812
  *TWIST2* (Median)           522   55            0.9 - 407

\* SD: standard deviation.

TWIST1 and TWIST2 expression and their associations with clinicopathologic features in patients {#s2_2}
-----------------------------------------------------------------------------------------------

The average expressions of *TWIST1* and *TWIST2* were 168.2 (range: 4.1 -6812) and 55 (range: 0.9 -- 407), respectively, in these patients (Table [1](#T1){ref-type="table"}). Associations of *TWIST1* and *TWIST2* were analyzed and the results are shown in Table [2](#T2){ref-type="table"}. *TWIST1* and *TWIST2* levels in female and male patients were almost identical (p=0.846 for *TWIST1* and p=0.856 for *TWIST2*). No significant differences in *TWIST1* or *TWIST2* were found between Caucasian and other. Smokers (including ever and current smokers), however, had significantly higher levels of *TWIST2* than non-smokers (p = 0.015); while TWIST1 is not found different between the two groups. In addition, *TWIST1* and *TWIST2* levels were not significantly related to the stage of HDNC (I-IV). However,*TWIST2* levels were significantly associated with tumor grade (p \<0.0001) with the lowest levels in Grade III. Neither tumor location nor metastasis stage was associated with *TWIST1* or *TWIST2* expressions. Radiotherapy did not change *TWIST1* or *TWIST2* expression.

###### Associations of *TWIST1* and *TWIST2* expressions with clinicopathologic variables

  Variable           N     *TWIST1*      *TWIST2*                 
  ------------------ ----- ------------- ---------- ------------- ----------
  Gender             521                 0.846                    0.856
  Female             137   2.20 (0.33)              1.70 (0.37)   
  Male               384   2.19 (0.39)              1.69 (0.42)   
  Race               506                 0.994                    0.688
  Caucasian          446   2.19 (0.37)              1.69 (0.41)   
  Other              60    2.19 (0.42)              1.71 (0.36)   
  Smoking            508                 0.377                    0.015
  No                 117   2.22 (0.34)              1.62 (0.44)   
  Yes                391   2.18 (0.38)              1.72 (0.39)   
  Disease Stage      507                 0.417                    0.266
  I                  20    2.13 (0.28)              1.85 (0.36)   
  II                 98    2.16 (0.41)              1.72 (0.39)   
  III                105   2.16 (0.39)              1.69 (0.42)   
  IV                 284   2.22 (0.37)              1.68 (0.40)   
  Tumor Grade        517                 0.275                    \<0.0001
  I                  63    2.12 (0.32)              1.72 (0.36)   
  II                 304   2.20 (0.37)              1.76 (0.37)   
  III                150   2.21 (0.42)              1.57 (0.45)   
  Tumor site         521                 0.156                    0.107
  Tongue             200   2.19 (0.37)              1.65(0.43)    
  Pharynx            135   2.14 (0.41)              1.74(0.36)    
  other              186   2.22 (0.35)              1.71(0.40)    
  Metastasis Stage   516                 0.693                    0.348
  M0                 490   2.19 (0.37)              1.70 (0.40)   
  M1-MX              26    2.16 (0.52)              1.62 (0.43)   
  Radiotherapy       183                 0.118                    0.304
  No                 62    2.15 (0.41)              1.73(0.40)    
  Yes                121   2.25 (0.41)              1.67(0.38)    

^1^Mean(SD): mean (standard deviation) in log10.

Associations of TWIST1 and TWIST2 with patient survival {#s2_3}
-------------------------------------------------------

To examine the associations of *TWIST1* and *TWIST2* gene expression with overall survival, we first performed Kaplan-Meier survival curves analyses stratified by either *TWIST1* or *TWIST2* expression levels. The results showed that patients with high *TWIST1* levels had inferior overall survival than those with low *TWIST1* (log-rank p = 0.076) (Figure [1A](#F1){ref-type="fig"}). The medians overall survival were 47.9 months (95% CI: 28.0 -- 67.8 months) for those with high *TWIST1* and 56.9 months (95% CI: 48.2 -- 84.4 months) for those with low *TWIST1*, respectively. The medians of overall survival were 52.3 months (95% CI: 45.9 -- 100.5 months) for those with high *TWIST2* and 56.9 months (95% CI: 35.5 -- 69.7 months) for those with low *TWIST2*, respectively. However, the survival curves were markedly separated with the superior overall survival for patients with high *TWIST2* after approximately 60 months compared to those with low. No statistically significant association was found between *TWIST2* expression and overall survival (Figure [1B](#F1){ref-type="fig"}, log-rank p = 0.107).

###### Kaplan-Meier overall survival curves stratified by either *TWIST1* (A) or *TWIST2* (B) expression levels

In comparison to low expression, High *TWIST1* expression had inferior overall survival (log-rank p = 0.076), while high *TWIST2* had slightly but not statistically significant superior but overall survival at the beginning and after 60 months of follow-up (log-rank p =0.107).
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Since gender and smoking status have effects on HNSCC \[[@R24], [@R25]\], we then checked the associations of *TWIST1* and *TWIST2* expression levels with overall survival in subgroups of either gender or smoking status. We found that in the subgroups of males and smokers, patients with high *TWIST1* had worse survival than those with low *TWIST1*. In male patients with high *TWIST1*, the median overall survival was 52.3 months (95% CI: 28.3 -- 67.8 months), whereas in male patients with low *TWIST1*, the median survival was 68.4 months (95% CI: 54.9 -- 95.3 months) (Figure [2A](#F2){ref-type="fig"}, log-rank p = 0.011). In smoker patients with high *TWIST1*, the median overall survival was 47.0 months (95% CI: 28.3 -- 65.8 months), whereas in smoker patients with low *TWIST1*, the median survival was 64.8 months (95% CI: 45.9 -- 156.4 months) (Figure [2B](#F2){ref-type="fig"}, log-rank p = 0.024). However, in the subgroups of either female or non-smokers, no statistically significant association was found between *TWIST1* expression and overall survival (data not shown). In the subgroup of nonsmoker patients, those with low *TWIST2* expression had inferior overall survival, compared with those with high *TWIST2* (log rank p = 0.004) (Figure [2C](#F2){ref-type="fig"}); the survival rate did not reach 0.5 for the group with high *TWIST2*, and the median of overall survival was ∞ (95% CI: 49.4 - ∞ months) for high *TWIST2*. In contrast, the median survival time for the group with low *TWIST2* was 35.5 months (95% CI: 19.0 -- 68.4 months). However, no statistically significant associations were found between *TWIST2* and overall survival in the subgroups of smoker patients, or male or female patients (data not shown).

###### Kaplan-Meier overall survival curves stratified by either *TWIST1* or *TWIST2* in the subgroup of gender and smoking status

High *TWIST1* had significantly inferior overall survival than low *TWIST1* in male patients **(A)** (log-rank p = 0.011), and smoker patients **(B)** (log-rank p = 0.024) compared to low *TWIST1*, respectively. In nonsmoker patients, high *TWIST2* had significantly superior overall survival in comparison to low one **(C)** (log-rank p = 0.004).
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We further performed multivariate Cox proportional hazard models to validate the Kaplan-Meier survival curves analyses with the adjustment of potential confounding variables and stratified by either gender or smoking status. Similarly, the multivariate Cox analysis showed that high *TWIST1* increased the risk of death, while high *TWIST2* decreased the risk of death (Table [3](#T3){ref-type="table"}). The HRs were 1.37 (95% CI: 1.02 -- 1.84) for high *TWIST1* in comparison to low one (p = 0.038), and 0.74 (95% CI: 0.55 -- 1.01) for high *TWIST2* compared to low one (p = 0.055) with the adjustment of patients' age at diagnosis, disease stage, tumor grade, tumor site, gender and smoking status. When patients were stratified by either gender or smoking status, those with high *TWIST1* had significantly elevated risk of death compared to those with low *TWIST1* in male (HR = 1.59, 95% CI: 1.12 -- 2.25) (p = 0.010) and borderline significant elevated risk in smoker (HR = 1.38, 95% CI: 0.99 -- 1.94) (p =0.058) subgroups (Table [4](#T4){ref-type="table"}) after adjusting covariates. In nonsmokers, patients with high *TWIST2* had significantly decreased risk of death compared to those with low one; the adjusted HR was 0.38 (95% CI: 0.18 -- 0.80) (p = 0.011). However, when we stratified the patients with either *TWIST1* or *TWIST2* levels, we observed that there were no significant associations between either gender or smoking status and the risk of death in the multivariate Cox proportional hazard analyses (data not shown).

###### Associations of *TWIST1* and *TWIST2* expressions with the risk of death

  Variable                  HR^1^   95% CI^2^      p value
  ------------------------- ------- -------------- ---------
  TWIST1 (high vs low)      1.37    1.02 - 1.84    0.038
  TWIST2 (high vs low)      0.74    0.55 -- 1.01   0.055
  Smoking (yes vs no)       1.17    0.81 - 1.68    0.403
  Gender (male vs female)   0.87    0.63 - 1.20    0.406
  Age (per 5 years)         1.10    1.02 - 1.18    0.010
  Stage                     1.06    0.90 - 1.25    0.459
  Grade                     1.02    0.82 - 1.26    0.886
  Tumor site                                       
  Tongue                    1.00                   
  Pharynx                   0.97    0.65 -- 1.44   0.865
  Other                     1.18    0.84 -- 1.67   0.345

^1^HR, hazard ratio, which was estimated in multivariate Cox proportional hazard regression analysis.

^2^CI: confidence interval.

###### Associations of *TWIST1* and *TWIST2* expressions with the risk of death stratified by either gender or smoking status

  Stratefied variabel   Variable                 adj-HR^1^   95% CI^2^     p value
  --------------------- ------------------------ ----------- ------------- ---------
  Gender^3^                                                                
   Female               *TWIST1* (high vs low)   1.07        0.61 - 1.88   0.802
                        *TWIST2* (high vs low    0.68        0.38 - 1.20   0.181
   Male                 *TWIST1* (high vs low)   1.59        1.12 - 2.25   0.010
                        *TWIST2* (high vs low)   0.74        0.51 - 1.05   0.094
  Smoking status^4^                                                        
   No                   *TWIST1* (high vs low)   0.67        0.32 - 1.44   0.309
                        *TWIST2* (high vs low    0.38        0.18 - 0.80   0.011
   Yes                  *TWIST1* (high vs low)   1.38        0.99 - 1.94   0.058
                        *TWIST2* (high vs low)   0.90        0.64 - 1.27   0.559

^1^adj-HR: adjusted hazard ratio, which was estimated in multivariate Cox proportional hazard regression analyses.

^2^CI: confidence interval.

^3^covariates included patient age (per 5 years), disease stage, tumor grade, smoking status and tumor site.

^4^covariates included patient age (per 5 years), disease stage, tumor grade, gender, and tumor site.

DISCUSSION {#s3}
==========

In this study, we demonstrated the associations of the two isoforms of a critical EMT regulators, *TWIST1* and *TWIST2*, with clinicopathological characteristics and overall survival in HNSCC and their interactions with either gender or smoking in the risk of death using a publicly accessed TCGA Head and Neck squamous cell carcinoma dataset. We found that *TWIST1*, but not *TWIST2*, was significantly positively linked to overall survival of these patients. Further analysis stratified with gender and tobacco use revealed this significant correlation only existing in males or smokers but not significantly in female or non-smokers. Unexpectedly, although *TWIST2* levels were not significantly related with overall survival, higher *TWIST2* levels were correlated with lower grade in overall patients and better survival in non-smokers; interestingly, this beneficial relation of *TWIST2* with survival is lost in smokers.

Generally, disease stage and age are important unfavorable prognostic marker in human cancer. Unexpectedly, disease stage was not significantly associated with the risk of death in this study. However, we did find that patients' age at diagnosis increased the mortality of HNSCC. These results suggest that the finding might not result from by chance. In addition, we could not rule out the possibility that the sample size in early stage (stage I: 20/507; stage II: 98/507) was relatively small, while the majority of patients were diagnosed at advanced stage in this study, which might result in insufficient power to detect an association between disease stage and risk of death. Furthermore, more than 25% of stage I and II oral cavity cancer patients can develop recurrence, a culprit of death \[[@R28]\].

To our knowledge, this is the first study to evaluate the respective role of *TWIST1* and *TWIST2* in HNSCC with a relatively large sample size. Unlike many studies which include patients who were followed up to 36 or 70 months, as long as up to 210.8 months were followed up for the patients.

Since TWISTs were reported as the master regulator in tumor metastasis in 2004 \[[@R29]\], multiple studies have demonstrated TWIST as a potential prognostic marker for many cancers, including myeloid leukemia, oral, esophageal, lung, breast, cervical and bladder cancer \[[@R27], [@R30]--[@R34]\]. TWIST enhances carcinoma metastasis by promoting cell proliferation, migration, invasion and colony formation. High TWIST protein expression has been shown in a positive correlation with poor prognosis in many cancers, including HNSCC \[[@R7], [@R26], [@R27], [@R35]--[@R37]\]. TWIST1 and TWIST2 share more than 90% sequence homology and structural similarity, and they have similar biochemical properties *in vitro*, and overlap in localization and expression pattern \[[@R14], [@R15], [@R38]\]. Thus, it was thought that overexpression of TWIST1 and/or TWIST2 was similarly correlated to poor prognosis in HNSCCs \[[@R36], [@R37]\]. In several meta-analysis studies, TWIST1 and TWIST2 were treated as identical and the data were combined together \[[@R27], [@R39]\]. However, there is evidence indicating that the two isoforms function differentially in carcinoma metastasis \[[@R40]\]. For example, the prognostic value of TWIST1 has been consistently demonstrated in many cancers; while although TWIST2 was also a prognostic marker in certain types of cancer, it was not associated with invasion and metastasis in hepatocellular carcinoma \[[@R16]\]. Moreover, TWIST2 was reported to inhibit tumor formation in a mouse osteosarcoma model \[[@R17]\]. In acute lymphoblastic leukemia, overexpression of TWIST2 inhibits cell growth, prompts apoptosis and increases sensitivity to chemotherapeutic agents \[[@R18]\]. TWIST2 may act as a tumor repressor by activating known tumor-suppressor genes \[[@R17], [@R19]\]. Indeed, the prognostic value of *TWIST* in HNSCC is still controversial or even opposite. Some paper reported the association of TWIST1 with poor prognosis in ESCC patients \[[@R12], [@R41], [@R42]\]; whereas there are also studies showing that TWIST is not associated with EMT of esophageal adenocarcinoma \[[@R43]--[@R45]\]. In our study, we found that higher *TWIST1* was associated with poor survival and this relationship was more noticeable in smokers or males; unexpectedly, higher *TWIST2* indicates a better survival in non-smokers. Based on the findings in this study, *TWIST1* showed a risk factor increasing the mortality in HNSCC, particularly in male patients, whereas *TWIST2* exhibited a protective role in decreasing the mortality in HNSCC, particularly in non-smoker patients.

In our study, we analyzed whether gender and smoking could modify the effect of *TWIST1/2* levels on the risk of death in HNSCC patients. In consistent with other studies \[[@R26], [@R27]\], our analysis did not find an impact of either gender or smoking on the risk of death. In addition, TWIST1 expression was not associated with gender in this study, which is in the agreement with the other previous results that TWIST expression was not related to gender in nasopharyngeal cancer \[[@R26]\]. However, we found that higher TWIST1 was linked to poor survival only in males but not in females. Taken together, our study firstly suggests that gender might be a modifier rather than a confounder in the effect of TWIST1 expression on patient survival in HNSCC.

Smoking is a known primary risk factors for HNSCC \[[@R46], [@R47]\], and tobacco use is reported in correlation with higher TWIST expression. Benzo(a)pyrene (BaP), one of the major chemical substance in cigarette, was found to enhances cell migration and invasion as well as TWIST expression in non-small cell lung cancer (NSCLC) cell line A549. In addition, the knockdown of TWIST blocked the migration and invasion of A549 cells induced by BaP \[[@R48]\], implying that smoking may cause EMT through TWIST. Our study revealed that the mRNA levels of *TWIST1* were not affected by smoking. This is in consistent with study from the other lab \[[@R49]\]. However, the inverse relationship of *TWIST1* with survival becomes even more noticeable in smokers. Interestingly, although *TWIST2* level is slightly higher in smokers than in non-smokers, the beneficial role of *TWIST2* on survival rate is still lost in smokers. These data suggest that smoking may modify the effect of *TWIST2* expression on the patient survival in HNSCC.

In summary, this study revealed that *TWIST1* and *TWIST2* were differently involved in prognostic of HNSCC with high *TWIST1* linking to poor survival, which is more obvious in either males or smokers than in either female or non-smokers. In addition, high *TWIST2* seems to decrease the risk of death in non-smoker but not in smoker patients. These findings suggest *TWIST1* and *TWIST2* are potential prognostic markers of HNSCC, and gender and smoking status can modify the effect of *TWIST1* and *TWIST2* expression on the risk of death in HNSCC.

MATERIALS AND METHODS {#s4}
=====================

Gene expression and clinicopathologic data {#s4_1}
------------------------------------------

We retrieved upper quartile normalized RNA-seq V2 RSEM values of *TWIST1* and *TWIST2* expressions from a TCGA Head and Neck squamous cell carcinoma dataset, which is available at TCGA provisional (<http://www.cbioportal.org/>). Experimental data generation and processing were conducted as previously described \[[@R50]\]. After downloading clinicopathologic data on these patients, we assembled gene expressions and clinicopathologic data for data analyses.

Statistical analyses {#s4_2}
--------------------

Statistical analyses were performed using SAS version 9.2 (SAS Institute, inc). The overall survival in months was calculated as the time from surgery until the occurrence of death. General linear models (GLM) were used to analyze the associations of *TWIST1* and *TWIST2* with clinicopathologic features and general characteristics of patients, in which the expressions of *TWIST1* and *TWIST2* were further converted by logarithm. The logarithm conversion was made after one plus each of the values to avoid impossible conversion for those with a value of zero. The median of either *TWIST1* or *TWIST2* expression levels was used as a cutoff value in classifying patients into two groups, low or high, in survival analyses. Kaplan-Meier survival curves were used to assess the associations of *TWIST* genes with patient survival, and multivariate Cox proportional hazards regression models were used to estimate the hazards ratios (HRs) and their 95% confidence intervals (95% CIs) with the adjustment for patients' age at diagnosis, disease stage, tumor grade, gender, smoking status and tumor site. A p value of less than 0.05 was considered statistically significant.
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